Filing Details
- Accession Number:
- 0001209191-21-068918
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-09 21:21:30
- Reporting Period:
- 2021-12-07
- Accepted Time:
- 2021-12-09 21:21:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1601830 | Recursion Pharmaceuticals Inc. | RXRX | Biological Products, (No Disgnostic Substances) (2836) | 464099738 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1837016 | Y Dean Li | C/O Recursion Pharmaceuticals 41 S. Rio Grande Street Salt Lake City UT 84101 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Disposition | 2021-12-07 | 14,900 | $20.44 | 1,316,000 | No | 4 | S | Indirect | By Dean Y. Li 2021 GRAT |
Class A Common Stock | Disposition | 2021-12-07 | 1,000 | $21.06 | 1,315,000 | No | 4 | S | Indirect | By Dean Y. Li 2021 GRAT |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By Dean Y. Li 2021 GRAT |
No | 4 | S | Indirect | By Dean Y. Li 2021 GRAT |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Class A Common Stock | 1,422,048 | Indirect | By Dean Li and Ruth Li Revocable Trust |
Class A Common Stock | 450,000 | Indirect | By Dean Y. Li 2021 Family Trust |
Class A Common Stock | 597,263 | Direct |
Footnotes
- Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
- The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.01 to $20.995 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
- The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $21.03 to $21.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.